Adaptimmune Therapeutics
ADAP
$0.98
Share price
8.72%
Change (1 day)
-31.70%
Change (1 year)
Categories
Revenue for Adaptimmune Therapeutics (ADAP)
Revenue in 2023 (TTM): $60.28 M
According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM) is $60.28 M. In 2022 the company made a revenue of $27.14 M an increase over the years 2021 revenue that were of $6.14 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Adaptimmune Therapeutics from 2016 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $60.28 M | 122.05% |
| 2022 | $27.14 M | 341.5% |
| 2021 | $6.14 M | 55.36% |
| 2020 | $3.95 M | 252.76% |
| 2019 | $1.12 M | -98.11% |
| 2018 | $59.5 M | 57.28% |
| 2017 | $37.83 M | 166.47% |
| 2016 | $14.19 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 uniQure QURE | $15.84 M | -73.72% | 🇳🇱 Netherlands |
 Novavax NVAX | $0.69 B | 1,050.38% | 🇺🇸 USA |
 Exelixis EXEL | $1.83 B | 2,936.13% | 🇺🇸 USA |
 Enzo Biochem ENZ | $12.8 M | -78.76% | 🇺🇸 USA |